Management Team

Brian Windsor, Ph.D.

Chief Executive Officer

Brian Windsor, Ph.D.

Brian Windsor, Ph.D.

Chief Executive Officer

Dr. Brian Windsor has served as President and CEO of Lung Therapeutics since July of 2013. He has spent the last 20 years in the formation and management of life science companies and has led technology development and licensing to major pharmaceutical and biotech companies.  Dr. Windsor brings leadership experience in pharmaceutical drug development, and he previously served as President of Enavail, LLC, a specialty pharmaceutical manufacturing company developing unique formulations for superior drug performance. While at Enavail, Dr. Windsor oversaw all aspects of pharmaceutical drug development, including drug selection, regulatory strategy, preclinical and clinical strategy, GMP manufacturing, and strategic partnering for pharma products.

Prior to his role with Enavail, Dr. Windsor directed portfolio company management for Emergent Technologies Inc. (ETI), an early stage technology venture creation and management company. During his tenure at ETI, Dr. Windsor served as Managing Director or President for ten of ETI’s portfolio companies and was involved in the conception, technology licensing, corporate and technical strategic planning, launch, and business development of all of these ventures. Applications areas of these companies span diverse segments within life and material sciences and include pharmaceutical development and manufacturing, drug delivery, and biotechnology. 

Prior to joining ETI, he was Founder and Vice President of R&D for Texagen, Inc., a startup focused on genetic and chemical methods for overcoming mechanisms of drug resistance important to medicine and agriculture. At Texagen, he directed outsourced research efforts at university labs and third-party contract research companies, and he interfaced with corporate partners interested in feasibility studies and in-licensing discussions.

He holds a Ph.D. in Molecular Biology from The University of Texas at Austin and is an inventor on multiple patents and patent applications.

Charles Garner

Chief Financial Officer

Charles Garner

Charles Garner

Chief Financial Officer

Charles Garner joined Lung Therapeutics in 2018 as Chief Financial Officer. Mr. Garner brings over 20 years of investment banking, corporate finance, business development and financial operational experience to Lung Therapeutics. Most recently, Mr. Garner was a life science industry consultant to private and public life sciences companies, providing financial and advisory services. Before this, Mr. Garner was Chief Financial Officer and Chief Business Officer for Recro Pharma, Inc., successfully leading the company’s initial public offering and acquisition of select assets from Alkermes, plc. Mr. Garner began his professional career as a certified public accountant with PricewaterhouseCoopers and, while an investment banker for Deutsche Bank AG, raised or advised on over $8 billion of financial and advisory transactions for healthcare clients. Mr. Garner received his Bachelor’s degree in Business Administration, high distinction, with a concentration in Accounting and Finance from the University of Michigan.

Laura Emery

Head of Clinical Operations

Laura Emery

Laura Emery

Head of Clinical Operations

Laura Emery, Head of Clinical Operations, brings over 27 years of experience in drug development, clinical operations and leadership skills, almost exclusively with start-up and small biotech companies.  She has held direct management responsibilities for global studies across all phases and multiple indications, with expertise in and passion for rare diseases. Ms. Emery holds long-standing, positive and collaborative relationships within the industry and a proven track record of successful clinical program execution leading to marketing approvals.  Prior to joining Lung Therapeutics, Ms. Emery held Director level roles in Clinical Operations for several start-ups including ARCA Biopharma, Aires Pharmaceuticals and Shield Therapeutics. In these roles she was responsible for building clinical teams, outsourcing as necessary, and clinical program design and implementation to ensure achievement of product development milestones. Early in her career, Ms. Emery was with a Colorado-based start-up, Myogen, Inc. (subsequently acquired by Gilead) for seven years where she acquired her rare disease expertise, working on the team who developed ambrisentan for pulmonary arterial hypertension.  She holds an MS in Public Health and an BA in Biology from the University of Colorado.

Matt Karpen

Director of CMC

Matt Karpen

Matt Karpen

Director of CMC

Matt Karpen joined Lung Therapeutics in 2018 as Director of CMC. Mr. Karpen brings approximately 20 years of biopharmaceutical experience to Lung Therapeutics, including various leadership positions in process development, process engineering, process scale-up, and technology transfer, cGMP operations support, and clinical and commercial manufacturing. Most recently, Mr. Karpen was a senior leader in the process validation strategy group within technical operations at Shire. There he developed and implemented innovative process qualification, characterization and controls strategies in support of several orphan drug and breakthrough therapies submissions. Prior to this, Mr. Karpen held various leadership roles at Amgen where he developed and implemented industry-leading strategies for process scale-up and tech transfer, product changeover and new product introduction, and supported the “manufacturing of the future” platform. At Amgen, Mr. Karpen was part of several successful commercial regulatory submissions. Mr. Karpen began his biopharmaceutical career at Pfizer within the process development organization and performed pilot plant operations, tech transfer and supported the start-up of a cGMP clinical manufacturing facility. Mr. Karpen received his Bachelor of Science in Engineering from the University of Dayton. He is published in BioPharm International and is a co-author of PDA Technical Report 56.

Misty Hickman

Director of Operations

Misty Hickman

Misty Hickman

Director of Operations

Misty Hickman has provided accounting and operational consulting services to Lung Therapeutics since 2013.  In 2019, Ms. Hickman came on-board full time as Director of Operations, and is now responsible for all aspects of business operations, including legal and vendor support, HR, and compliance.  She also continues to support the finance and accounting functions where needed. Ms. Hickman began her career in public accounting and spent several years with a local firm in Louisiana before moving to Texas in 2006.  Since then, she has worked for and consulted for several startups and pre-revenue companies, with a focus on establishing scalable policies and procedures for young companies.  She has over 20 years of experience in finance, accounting, and operations.  Ms. Hickman received her Bachelor of Science in Business Administration with a concentration in Accounting degree from the University of Louisiana at Lafayette.